




6673838









Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
Ittorney Docket No.: AM100463
itle: Novel Succinate Salt of O-Desmethyl-Venlafax










Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
Attorney Docket No.: AM100463
Title: Novel Succinate Salt of O-Desmethyl-Venlai



Application No.: N/A Customer No.: 25291 Inventors: Anthony F. Hadfield, etal crney Docket No.: AM100463

: Novel Succinate Salt of O-Desmethyl-Venlafaxine





FIG.7

Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
ney Docket No.: AM100463
Novel Succinate Salt of O-Desmethyl-Venlafaxine

8/12



Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
ttorney Docket No.: AM100463
le: Novel Succinate Salt of O-Desmethyl-Venlafaxin

9/12

RAT JEJUNAL ABSORPTION OF ODV SUCCINATE AND INTERNAL MARKERS [ODV SUCCINATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8




FIG.9

INTESTINAL SITE-SPECIFIC ABSORPTION OF ODV SUCCINATE [ODV SUCCINATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8




FIG.10

Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
rney Docket No.: AM100463
Novel Succinate Salt of O-Desmethyl-Venlafaxine

10/12




FIG.11

INTESTINAL SITE-SPECIFIC ABSORPTION OF ODV FUMARATE [ODV FUMARATE] = 50 ug/ml, PERFUSION BUFFER, pH6.8





FIG.12

Application No.: N/A Customer No.: 25291 Inventors: Anthony F. Hadfield, etal Attorney Docket No.: AM100463 Title: Novel Succinate Salt of O-Desmethyl-Venlage.



Application No.: N/A Customer No.: 25291
Inventors: Anthony F. Hadfield, etal
princy Docket No.: AM100463
E: Novel Succinate Salt of O-Desmethyl-Venlafaxing

12/12

MW 58.44 MW 18.02 + NaCl + H20 C16H25N02 MW 263.381 MW 40.00 + NaOH

FIG.14

C₁₆H₂₆CINO₂ MW 299.84

<u>,</u>